Researchers have recently come up with a dog medicine designed at significantly increasing a canine's life expectancy through a project dubbed as the Dog Aging Project. The project is focusing on testing the chemical on volunteer crowdsourced dogs to accumulate research on the substance's performance.
According to data already collected on rapamycin, the life expectancy of a dog can be increased by 30% and it can help improve the signs of diseases and aging when administered into the body. The statistics relay to giving dogs of larger sizes up to three extra years on their lifespan, and smaller dogs an added four years. Rapamycin is also proven to improve a canine's health overall as well as being used as a preventative method for large scale sicknesses such as obesity and cancer.
Key Themes Behind This Trend
- Life-extending Dog Medicines
- Opportunity for pharmaceutical companies to develop and market innovative dog medicines that can extend a canine's life expectancy.
- Crowdsourced Dog Aging Project
- Opportunity for research organizations to collaborate and collect data through crowdsourcing to study the effects of rapamycin on canine aging.
- Preventative Veterinary Care
- Opportunity for veterinary clinics to offer rapamycin as a preventative treatment to improve overall health and decrease the risk of obesity and cancer in dogs.
Where This Applies
- Pharmaceuticals
- Pharmaceutical companies can incorporate rapamycin into their product offerings to cater to the growing demand for life-extending dog medicines.
- Research
- Research organizations can participate in the Dog Aging Project to gather scientific evidence on the benefits of rapamycin and its effects on canine aging.
- Veterinary
- Veterinary clinics can integrate rapamycin as part of their preventative care approach to enhance the well-being and lifespan of dogs.
